An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19

by Weihui Fu, Yan Liu, Li Liu, Huiliang Hu, Xiaobo Cheng, Ping Liu, Zhigang Song, Lijun Zha, Shimeng Bai, Tingting Xu, Songhua Yuan, Fengru Lu, Zhiying Shang, Yihong Zhao, Jing Wang, Jun Zhao, Longfei Ding, Jun Chen, Lin Zhang, Tongyu Zhu, Xiaoyan Zhang, Hongzhou Lu, Jianqing Xu
Published 2020-10-01